Replicor宣布发表模型研究报告，证明NAP可以有效抵抗HBV和HDV感

StephenW

Replicor announces publication of modelling study demonstrating potent activity of NAPs against HBV and HDV infection

MONTREAL, May 12th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, today announced the publication of the modelling of antiviral responses to REP 2139 monotherapy in HBV / HDV co-infection in the journal Scientific Reports (www.nature.com/articles/s41598-020-64122-0).

This article, entitled “Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg” models the HBsAg and HDV RNA responses during REP 2139-Ca monotherapy in the REP 301 study (NCT02233075, https://doi.org/10.1016/S2468-1253(17)30288-1) and was conducted in collaboration with the lab of Dr. Harel Dahari, Associate Professor, Program for Experimental and Theoretical Modelling in the Department of Medicine, Division of Hepatology at Loyola University Chicago.

The study established a model accurately predicting antiviral responses observed during REP 2139 modelling which included highly efficient inhibition of both HBsAg (98.2%) and HDV (99.7%).  Importantly, modelling in this study confirmed the rapid turnover of HBsAg (subviral particles) in the blood observed in previous independent studies of HBV monoinfection, establishing a T1/2 of 1.3 days.

Dr. Andrew Vaillant, CSO at Replicor commented, “The modelling work conducted in Dr. Dahari’s lab is helping us better understand the clinical effects of NAPs in both HBV and HDV infection.  Our work continues with Dr. Dahari’s lab to model the antiviral responses in the recently published REP 401 study (NCT02565719, https://doi.org/10.1053/j.gastro.2020.02.058) where high rates of functional cure of HBV were established with NAP-based combination therapy.  The confirmation of the very rapid turnover of subviral particles by this modelling study strengthens the notion that clearance of HBsAg depends not only on the blockade of replenishment of subviral particles into the blood but the active clearance of subviral particles from the blood.”  

About Replicor

Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

StephenW

Replicor宣布发表模型研究报告，证明NAP可以有效抵抗HBV和HDV感染

蒙特利尔，2020年5月12日–一家私有生物制药公司Replicor Inc.今天宣布宣布该模型的发布，该公司致力于治疗慢性乙型肝炎病毒（HBV）和慢性HBV和丙型肝炎三角洲病毒（HDV）合并感染的患者《科学报告》（www.nature.com/articles/s41598-020-64122-0）中对HBV / HDV共感染的REP 2139单一疗法的抗病毒反应的评估。

这篇题为“在核酸聚合物单药治疗期间对D型肝炎病毒RNA和HBsAg动态进行建模，表明HBsAg的快速更新”在REP 301研究中为REP 2139-Ca单药治疗期间的HBsAg和HDV RNA反应建模（NCT02233075，https：// doi .org / 10.1016 / S2468-1253（17）30288-1），是与洛约拉大学肝病学系医学实验和理论建模计划副教授Harel Dahari博士的实验室合作进行的芝加哥。

该研究建立了一个模型，该模型可准确预测在REP 2139建模期间观察到的抗病毒反应，其中包括高效抑制HBsAg（98.2％）和HDV（99.7％）。重要的是，该研究中的模型证实了先前在HBV单感染的独立研究中观察到的血液中HBsAg（亚病毒颗粒）的快速转换，建立了1.3天的T1 / 2。

Replicor的CSO的Andrew Vaillant博士评论说：“在Dahari博士的实验室中进行的建模工作正在帮助我们更好地了解NAP在HBV和HDV感染中的临床效果。在最近发表的REP 401研究（NCT02565719，https：//doi.org/10.1053/j.gastro.2020.02.058）中，Dahari博士的实验室继续为抗病毒反应建模，我们的工作在此进行中，HBV的功能治愈率很高建立基于NAP的联合疗法。通过该建模研究证实了亚病毒颗粒非常快速的更新，这强化了以下观念：HBsAg的清除不仅取决于阻断亚病毒颗粒向血液中的补充，而且还取决于从血液中清除亚病毒颗粒的活性。 ”

关于复制品

Replicor是一家私有生物制药公司，在开发HBV和HDV的治疗方法方面拥有最先进的动物和人类临床数据。该公司致力于加快针对HBV和HBV / HDV合并感染患者的有效治疗方法的开发。有关Replicor的更多信息，请访问我们的网站www.replicor.com。

齐欢畅

灵魂不屈

感谢分享，希望早日上市。

乙肝人1949

脱半身，那半身呢?等的着急人

newchinabok

乙肝人1949 发表于 2020-5-14 13:26
脱半身，那半身呢?等的着急人

论坛很有战友离开5年，再回来看都不耽误。莫急，莫急，估计10年吧